Oncternal Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Oncternal Therapeutics

03/11/2022 21:04

* Oncternal Therapeutics Inc  ONCT.OQ  reported a quarterly
adjusted loss of 21 cents​​ per share for the quarter ended in
September. The mean expectation of six analysts for the quarter
was for a loss of 24 cents per share.
    * Revenue fell 82% to $382.00 thousand from a year ago;
analysts
expected $305.80 thousand. 
    * Oncternal Therapeutics Inc's reported EPS for the quarter
was a
loss of 21 cents​.
    * The mean earnings estimate of analysts had fallen by
about 1.4%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Oncternal Therapeutics Inc shares had risen by 14.4% this
quarter and lost 55.1% so far this year.
    * The company reported a quarterly loss of $11.13 million.
    * Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $7.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
3 at 09:03 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.24          -0.21          Beat
 Jun. 30 2022      -0.23          -0.23          Met
 Mar. 31 2022      -0.20          -0.20          Met
 Dec. 31 2021      -0.25          -0.16          Beat